Search
Myriad Genetics Inc
MYGNAdd to Watchlist
4.345USD
+0.095+2.22%
Market hours （ET）Quotes delayed by 15 min
410.12MMarket Cap
LossP/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
372.40M
45.17%
Prenatal
186.30M
22.60%
Pharmacogenomics
144.10M
17.48%
Tumor Profiling
121.70M
14.76%
By RegionUSD
Name
Revenue
Proportion
United States
768.00M
93.15%
Rest of world
56.50M
6.85%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
372.40M
45.17%
Prenatal
186.30M
22.60%
Pharmacogenomics
144.10M
17.48%
Tumor Profiling
121.70M
14.76%
